Carbamylated darbepoetin (recombinant human erythropoietin) or darbepoetin (100 ng/ml) could decrease telomere shortening and senescence induced by TNF-α and uremic serum in EPCs from non-dialysis chronic kidney disease patients. Here, EPO is linked to chronic kidney disease.